Hereditary sensory and autonomic neuropathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:140471
Who is this for?
Show terms as
3Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hereditary sensory and autonomic neuropathy (HSAN), also known as hereditary sensory neuropathy (HSN) or hereditary sensory and autonomic neuropathy group, encompasses a clinically and genetically heterogeneous group of rare inherited disorders that primarily affect the peripheral sensory and autonomic nervous systems. These conditions are characterized by progressive degeneration or abnormal development of sensory neurons (particularly small fiber neurons responsible for pain and temperature sensation) and, to varying degrees, autonomic neurons that control involuntary body functions such as sweating, blood pressure regulation, and gastrointestinal motility. HSANs are classified into several subtypes (HSAN types I through VIII and additional forms), each with distinct genetic causes, inheritance patterns, and clinical presentations. Common features across the group include reduced or absent pain and temperature sensation, which can lead to painless injuries, chronic skin ulcers, infections, and in severe cases, acral mutilation and osteomyelitis requiring amputation. Autonomic dysfunction may manifest as anhidrosis (inability to sweat), episodic fevers, postural hypotension, gastrointestinal disturbances, and impaired lacrimation. Some subtypes present at birth or in infancy with severe manifestations including feeding difficulties and failure to thrive, while others have a later onset with predominantly sensory symptoms. There is currently no cure for HSAN. Treatment is supportive and multidisciplinary, focusing on prevention and management of complications. This includes meticulous skin and wound care, protective footwear, regular monitoring for injuries and infections, pain management when neuropathic pain is present, and management of autonomic symptoms. Orthopedic interventions may be necessary for skeletal complications. Genetic counseling is recommended for affected families. Early diagnosis and preventive strategies are essential to minimize tissue damage and improve quality of life.

Also known as:

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

7 events
Nov 2025A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

AstraZeneca — PHASE1

TrialRECRUITING
Sep 20259-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Anwaar Saeed — PHASE1

TrialRECRUITING
Nov 2024Diffrence in Thromboprofilaksis in Elderly Ostoepenic Hip Fractures According to Mobility Status by Genetic Analysis

Saglik Bilimleri Universitesi — NA

TrialACTIVE NOT RECRUITING
Oct 2024Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Acrivon Therapeutics — PHASE1

TrialRECRUITING
May 2022A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

Zhuhai Yufan Biotechnologies Co., Ltd — PHASE1, PHASE2

TrialRECRUITING
Mar 2022A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors

Zhuhai Yufan Biotechnologies Co., Ltd — PHASE1

TrialACTIVE NOT RECRUITING
Oct 2020A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

Restorbio Inc. — PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Hereditary sensory and autonomic neuropathy.

View clinical trials →

No actively recruiting trials found for Hereditary sensory and autonomic neuropathy at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Hereditary sensory and autonomic neuropathy community →

Specialists

3 foundView all specialists →
BM
Benedetto Falsini, MD
Rome
Specialist

Rare Disease Specialist

PI on 2 active trials
DM
David Bajor, MD
CLEVELAND, OH
Specialist
PI on 2 active trials
NM
Norman Wolmark, MD
Phoenix, Arizona
Specialist

Rare Disease Specialist

PI on 13 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hereditary sensory and autonomic neuropathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hereditary sensory and autonomic neuropathyForum →

No community posts yet. Be the first to share your experience with Hereditary sensory and autonomic neuropathy.

Start the conversation →

Latest news about Hereditary sensory and autonomic neuropathy

Disease timeline:

New recruiting trial: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

A new clinical trial is recruiting patients for Hereditary sensory and autonomic neuropathy

New recruiting trial: A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

A new clinical trial is recruiting patients for Hereditary sensory and autonomic neuropathy

New recruiting trial: A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

A new clinical trial is recruiting patients for Hereditary sensory and autonomic neuropathy

New recruiting trial: 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

A new clinical trial is recruiting patients for Hereditary sensory and autonomic neuropathy

New recruiting trial: A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

A new clinical trial is recruiting patients for Hereditary sensory and autonomic neuropathy

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hereditary sensory and autonomic neuropathy

What is Hereditary sensory and autonomic neuropathy?

Hereditary sensory and autonomic neuropathy (HSAN), also known as hereditary sensory neuropathy (HSN) or hereditary sensory and autonomic neuropathy group, encompasses a clinically and genetically heterogeneous group of rare inherited disorders that primarily affect the peripheral sensory and autonomic nervous systems. These conditions are characterized by progressive degeneration or abnormal development of sensory neurons (particularly small fiber neurons responsible for pain and temperature sensation) and, to varying degrees, autonomic neurons that control involuntary body functions such as

Which specialists treat Hereditary sensory and autonomic neuropathy?

3 specialists and care centers treating Hereditary sensory and autonomic neuropathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.